The Regulating Action of Sodium Tanshinone IIA Sulfonate on the Level of Serum Inflammatory Foutor in Patients with Cardiorenal Syndrome

Objective: To observe the effect of sodium tanshinone IIA sulfonate on the level of serum inflammatory factor,interleukin-6(IL-6),tumor necrosis factor-alpha(TNF-α) and C-reactive protein(CRP) in cardiorenal syndrome patients.Method: 28 patients who were accepting standard heart failure therapy according to ACC/AHA and HFSA Heart Failure Practice Guideline and diagnosed as cardiorenal Syndrome(CRS),was divided into two groups randomly,dopamine treatment group and dopamine combined with sodium tanshinone IIA sulfonate treatment group(combined treatment group).The glomerular filtration rate,the level of serum IL-6,TNF-α and CRP was estimated in each group on 7th day after treatment.Result: Contrasted with dopamine treatment group,the levels of serum CRP,TNF-α,IL-6 were decreased significantly in combined treatment group(CRP:7.89 ± 9.6 vs 13.1± 8.6,P0.05;TNF-α:1.89 ± 1.98 vs 3.15 ± 1.49,P0.05;IL-6:3.03 ± 3.64 vs 4.96 ± 3.93,P0.05).Conclusion: Sodium tanshinone IIA sulfonate can relieve the systemic inflammatorome,may improve the short term prognosis by antiinflammatory action in cardiorenal syndrome patients.